IL6 and infection: Although our study focuses on the protective effect of monolaurin against COVID-19 infection, it is well known that some biological markers, especially interleukin-6 (IL-6), are strongly associated with adverse outcomes in SARS-CoV-2 infections [34], and there is evidence to suggest that monolaurin exerts both direct and indirect effects in reducing the synthesis of inflammatory cytokines [35], potentially leading to more favorable outcomes during infection.